John Rex

Antibiotic procurement models for LMICs / G7 Leaders call for Pull!

Dear All, Two stops on our tour today: (i) an excellent survey of incentive models and (ii) a final communique from the recent G7 meetings. First up, CGD (Center for Global Development) have released a report (link) entitled “Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures

Read More »

Leaky pipe(lines) / When is a molecule a drug? (Part 1 of 2)

Dear All, I was fascinated by this recent paper in AAC: Neha K. Prasad, Ian B. Seiple, Ryan T. Cirz, and Oren S. Rosenberg. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrob Agents Chemother. 2022 May 17;66(5):e0005422. doi:10.1128/aac.00054-22. (Addendum: This newsletter has a follow-up newsletter.) In brief,

Read More »

ATMF on Access in LMICs/Progress, but wishing for more

Dear All, Last fall, the team at ATMF (Access to Medicine Foundation) released the 3rd update to the AMR Benchmark series and Damiano de Felice was a guest author for a newsletter about the findings. That report offered a wealth of granular data, in-depth analyses and revealing graphs about what pharmaceutical companies in the global antibiotic and

Read More »

Climate change and AMR: NIH grant opportunity!

Dear All, A Notice of Special Interest (a “NOSI” in NIH jargon; here’s the link: NOT-ES-22-006) from the NIH could be something of interest for AMR R&D. This NOSI has > 10 of the Institutes behind it and as summarized on the website “this NOSI encourages applications that address the impact of climate change on health

Read More »

Antibacterial guidance (including pediatrics): Parallel EMA+FDA updates

Dear All (Wonkish alert! Get some coffee and settle in!), Almost in parallel, EMA and FDA have released updates to key antibacterial guidance documents! Here are the links you’ll need and I’ve highlighted the key documents. To go deeper, you’ll need to pick through everything and I provide a tour further below in this newsletter:  EMA’s

Read More »

CARB-X renewed x 10 years! Strong calls for PASTEUR!

Dear All, On the heels of yesterday’s (i) patient-focused meeting at the Capitol yesterday where 5 Members of Congress spoke in person (video, press release) in support of passage of the PASTEUR Act and (ii) strong shout-out to PASTEUR by Congressman Mike Doyle during the Energy and Commerce Committee markup session, CARB-X today announced commitments of

Read More »

3 June 2022 FDA workshop: Developing for uncomplicated UTI (uUTI)

Dear All, It doesn’t rain … it pours! Just seconds after sending out a newsletter on the 18 May et seq. Squash Superbugs Day of Action, I learned that FDA has announced a 3 June 2022 workshop on uUTI! From their webpage on the event: “The workshop will focus on nonclinical and clinical considerations regarding antimicrobial

Read More »
Scroll to Top